Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. The finding contrasts with positive results from previous phase II ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The findings of two recent studies give hope that the disease could one day be reversed in humans—but experts warn that this ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

GLP-1s are being studied for cardiovascular disease, liver conditions, kidney disease, and Alzheimer’s. Older approved GLP-1s from Novo Nordisk, Sanofi, and Amylin have been or are being ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the secret to staving off Alzheimer’s, too.

Popular diabetes medications, including GLP-1 drugs, may protect against Alzheimer's disease. ScienceDaily . Retrieved June 11, 2025 from www.sciencedaily.com / releases / 2025 / 04 / 250416135158.htm ...

Popular diabetes medications, including GLP-1 drugs, ... there is promising potential for GLP-1RAs and SGLT2is to be considered for Alzheimer’s disease prevention in the future.